Shanghai Sunway Biotech Co. Ltd. Release: First Oncolytic Viral Therapy Approved For Head And Neck Cancer

SHANGHAI, China--(BUSINESS WIRE)--Nov. 17, 2005--Shanghai Sunway Biotech Co. Ltd. announced today that the Chinese State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory Nasopharyngeal cancer, a type of head and neck cancer prevalent in China. This marks the first oncolytic viral therapy approved by any regulatory agency in the world.